Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VIRON, INC. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape for the company involves 2 pending office actions. Notably, both of these are assigned to a single individual, HIBBERT, CATHERINE S, who is identified as the busiest examiner for the portfolio. This creates a situation where the pending workload is concentrated under 1 distinct examiner and 1 distinct art unit.
The workload assigned to HIBBERT, CATHERINE S represents the total volume of active reviews for VIRON, INC. at this time. Having 1 distinct examiner manage the 2 pending office actions suggests that the company's current legal strategy in Biotechnology & Pharmaceuticals is focused on a specific examiner's perspective. The 1 distinct art unit involved further emphasizes this narrow channel of prosecution.
For practitioners, the fact that the busiest examiner pending count of 2 matches the total pending office actions is a significant data point. It indicates that there is no variance in examiner assignment across the current portfolio. All active matters are subject to the same examination style and art unit standards, which may streamline the response process for the 1 distinct art unit currently active.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573587 | FUNCTIONAL POROSOME MANIPULATION | HIBBERT, CATHERINE S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573587 | FUNCTIONAL POROSOME MANIPULATION | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573587 | FUNCTIONAL POROSOME MANIPULATION | HIBBERT, CATHERINE S | 1658 | §102§103§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVIRON, INC. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catherine S Hibbert has the most, with 1 of VIRON, INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
